DOCSLIB.ORG

Anti-COVID-19 Compound Library (96-Well)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Anti-COVID-19 Compound Library (96-Well) • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com Anti-COVID-19 Compound Library (96-well) Product Details: Catalog Number: CS-L052 Formulation: A collection of 1512 compounds that may have anti-COVID-19 activity supplied as pre-dissolved Solutions or Solid Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode Storage: -80°C Shipping: Blue ice Packaging: Inert gas Plate layout: CS-L052-1 1 2 3 4 5 6 7 8 9 10 11 12 Varenicline a Empty Vonoprazan Faropenem Flavopiridol Semagacesta Delpazolid DSM265 GSK- Varenicline (Hydrochlorid Varenicline Empty daloxate t 2881078 e) (Tartrate) AQ-13 b Empty dihydrochlorid Linaprazan BFH772 Cadazolid Treprostinil Paquinimod AEE788 Plerixafor GSK2256098 Aprepitant Empty e c Empty Flopropione Acriflavine Spiramycin Ticagrelor Axitinib Eganelisib HT-2157 CXD101 Ritlecitinib 3-AP Empty TAK-659 (2- d Empty BGP-15 (hydrochlorid Navitoclax Acelarin Olcegepant Sarcosine Hydroxypropy TG100-115 T807 JNJ- Empty e) l)-β- 39758979 Veliparib e Empty Asenapine Silodosin Barasertib- Barasertib Vadadustat Veliparib Iberdomide (dihydrochlori Ralfinamide Zanubrutinib Empty HQPA de) Ibuprofen f Empty piconol Avapritinib GSK3326595 Roblitinib Gefapixant Tozasertib Olaparib GSK2982772 Ziritaxestat Dasatinib Empty Dasatinib g Empty (hydrochlorid TG 100801 Miridesap Linsitinib Sepantronium Prostaglandin Navarixin AZD4635 Rucaparib Sorafenib Empty e) (bromide) E2 (Camsylate) Sorafenib h Empty (Tosylate) Cediranib Apimostinel Pazopanib BIIB021 Everolimus Rapamycin Panobinostat Belinostat Bortezomib Empty Plate layout: CS-L052-2 1 2 3 4 5 6 7 8 9 10 11 12 Edoxaban a Empty Saracatinib Danoprevir Simeprevir RAF265 Sunitinib Edoxaban Edoxaban (tosylate Betrixaban Dabigatran Empty (tosylate) monohydrate) etexilate Amibegron Bepridil b Empty Tarenflurbil Narlaprevir Gusacitinib Repotrectinib AAI101 Doramapimod hydrochloride Desidustat Regorafenib hydrochloride Empty Regorafenib Fasudil Canertinib Samuraciclib c Empty (monohydrate BMS-690514 Brivanib Foretinib Stiripentol (Hydrochlorid Sotrastaurin Raltegravir (dihydrochlori (hydrochlorid Empty ) e) de) e) Ensartinib d Empty hydrochloride Trimetrexate Semaxinib Sutezolid VX-702 Asciminib Islatravir Pamiparib Lanifibranor Pralatrexate Empty Dapagliflozin Daclatasvir e Empty Capsaicin Dapagliflozin ((2S)-1,2- Canagliflozin Ixazomib Ixazomib Delanzomib TAK-715 (dihydrochlori Eprotirome Empty propanediol, citrate de) Pevonedistat f Empty hydrochloride Dinaciclib Cobicistat Orteronel Orantinib Fidarestat Darapladib Telatinib Tasquinimod Eniluracil Empty Tariquidar Sarpogrelate Gatifloxacin g Empty Tariquidar (methanesulf (hydrochlorid Ponesimod Nevirapine Delavirdine Efavirenz (hydrochlorid Flurbiprofen 5-Azacytidine Empty onate, e) (mesylate) e) Niraparib h Empty Bimosiamose Rucaparib Niraparib (hydrochlorid Niraparib Larazotide SB-705498 Carcainium BIO-11006 Arimoclomol Empty (phosphate) e) (tosylate) (acetate) (chloride) (acetate) (maleate) Plate layout: CS-L052-3 1 2 3 4 5 6 7 8 9 10 11 12 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Tel: 732-484-9848 Fax: 888-484-5008 Email: [email protected] • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com Delapril a Empty Pridopidine (hydrochlorid Tetrahydrobio Abrocitinib Benorilate Inosine MSDC-0602 Pemetrexed Pemetrexed Raltitrexed Empty e) pterin pranobex (disodium) Nolatrexed Foliglurax b Empty Talazoparib Pretomanid dihydrochlorid Vipadenant (monohydroc Apararenone Rosiptor Tucidinostat Balovaptan Inarigivir Empty tosylate e hloride) soproxil Danegaptide Momelotinib c Empty Mavacamten Tapinarof Fulacimstat Vecabrutinib Hydrochloride Aniracetam CX516 Farampator Momelotinib sulfate Empty Obatoclax Pomalidomid d Empty Vadimezan Ensulizole (Mesylate) Crisaborole Tavaborole Lenvatinib Amonafide e Adavosertib Tozadenant Empty Trametinib Alendronate e Empty Ibrutinib Trametinib (DMSO ZSET1446 Fingolimod (sodium GLPG1837 Vabicaserin Tinoridine INCB-057643 Empty solvate) hydrate) hydrochloride hydrochloride Tafenoquine Calcium Retagliptin PF-06700841 f Empty (Succinate) dobesilate PTI-428 AZD-7648 GSK3145095 (phosphate) (P-Tosylate) ACT-709478 BI-409306 BI-671800 Empty Pyridoxal Fingolimod Erlotinib Metixene g Empty Imrecoxib Olutasidenib USL311 LY2452473 Eslicarbazepi isonicotinoyl BPN14770 (hydrochlorid (Hydrochlorid hydrochloride Empty ne hydrazone e) e) hydrate Pazopanib Vatalanib SB-743921 h Empty (Hydrochlorid Iniparib (dihydrochlori AMG-208 Elesclomol Pimasertib Cabozantinib (hydrochlorid BMS 777607 Anacetrapib Empty e) de) (S-malate) e) Plate layout: CS-L052-4 1 2 3 4 5 6 7 8 9 10 11 12 Aliskiren a Empty Entinostat Mocetinostat Aliskiren (hemifumarat Lorlatinib Telaglenastat Umbralisib Serabelisib Defactinib Setanaxib Empty e) Epetraborole Dantrolene Bephenium b Empty Pimodivir Siponimod TAS-114 E7449 Crenigacestat Balipodect (hydrochlorid (sodium (hydroxynaph Pyrantel Empty e) hemiheptahy thoate) (pamoate) Midodrine c Empty Mirogabalin Primaquine Molidustat LX7101 Entrectinib Bromocriptine (hydrochlorid Alimemazine BLZ945 Raxatrigine Empty (diphosphate) (mesylate) e) hemitartrate hydrochloride TAS4464 d Empty Antineoplasto TAS4464 (hydrochlorid Larotrectinib Larotrectinib PT-2385 Bimiralisib Eliprodil Ifenprodil ASLAN003 Empty n A10 e) sulfate (tartrate) Dinoprost Fostamatinib e Empty AMG319 (tromethamin Batefenterol Maraviroc Ivacaftor Rebastinib Idelalisib Gandotinib Fostamatinib (disodium Empty e salt) Disodium hexahydrate) Daunorubicin f Empty LX-1031 Telotristat (hydrochlorid Golvatinib MK-8245 Cobimetinib Zanamivir Crenolanib Galunisertib Talabostat Empty etiprate e) (racemate) (mesylate) Regorafenib g Empty Dolutegravir LY2886721 Ralimetinib Disufenton ABT-751 (Hydrochlorid Montelukast Oseltamivir Sapanisertib Varespladib Empty dimesylate sodium e) (sodium) acid Mitoxantrone ATN-161 h Empty Capmatinib Tofogliflozin AICAR Roxadustat Nedocromil Droxidopa Mitoxantrone (dihydrochlori Camostat (trifluoroaceta Empty (hydrate) (phosphate) de) (mesylate) te salt) Plate layout: CS-L052-5 1 2 3 4 5 6 7 8 9 10 11 12 Cefsulodin Cisatracurium a Empty Amsacrine β-Lapachone Biapenem Brivudine (sodium) Piclidenoson (besylate) Cladribine Cytarabine Deflazacort Empty Entecavir Epirubicin b Empty Dutasteride Efaproxiral Efaproxiral (monohydrate (hydrochlorid Exemestane Ezatiostat Ganciclovir Incyclinide Indisulam Empty (sodium) ) e) (-)- Levamisole 6- 6- c Empty Epigallocatec Lansoprazole (R)- (hydrochlorid Levoleucovori Lomustine Mercaptopuri Mercaptopuri Meropenem Nelarabine Empty hin Gallate Lansoprazole e) n (Calcium) ne ne hydrate (trihydrate) Pirarubicin Quinagolide Raloxifene d Empty Nilutamide SN-38 Norepinephri Oglufanide Pergolide (Hydrochlorid Pixantrone (hydrochlorid (hydrochlorid Resiquimod Empty ne (mesylate) e) (dimaleate) e) e) Sitagliptin Topotecan e Empty Silibinin Sitagliptin (phosphate Ebselen Tamoxifen Tamoxifen 6- Tirapazamine (Hydrochlorid Valrubicin Empty monohydrate) (Citrate) Thioguanine e) Zoledronic Pemetrexed Hydroxyfasud Empty acid (disodium Fexinidazole BMS-833923 Flumatinib Tenofovir Tenofovir Hydroxyfasud il Roniciclib Empty f (monohydrate hemipenta (mesylate) (hydrate) il (hydrochlorid Cinaciguat Vernakalant g Empty Napabucasin Merimepodib Tegaserod Zileuton Bexarotene (hydrochlorid (Hydrochlorid Macitentan Toloxatone Omecamtiv Empty (maleate) e) e) mecarbil Olprinone h Empty Fadrozole Letrozole Bicalutamide Milrinone (Hydrochlorid Vilazodone Pericyazine Lersivirine Febuxostat Lodoxamide Empty e) Plate layout: CS-L052-6 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Tel: 732-484-9848 Fax: 888-484-5008 Email: [email protected] • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com 1 2 3 4 5 6 7 8 9 10 11 12 BMS-582949 a Empty Ravuconazol Entacapone Trilostane Luliconazole Indacaterol Indacaterol Vilanterol (hydrochlorid Intepirdine GSK163090 Empty e (maleate) (trifenatate) e) b Empty Indomethacin Celecoxib Itanapraced Pavinetant Asunaprevir Bilastine Onalespib Methotrexate Sertindole Quetiapine Empty GTS-21 Pioglitazone c Empty Talnetant (dihydrochlori Donepezil E7820 Lopinavir Genistein Diethylstilbest Rosiglitazone (hydrochlorid Tramiprosate Empty de) rol (maleate) e) Resminostat d Empty Apilimod Apilimod Dexamethaso Tamibarotene Aspirin Sulfasalazine Thalidomide Fluvastatin Lomitapide (hydrochlorid Empty (mesylate) ne (sodium) e) Anamorelin Pyronaridine e Empty Rabusertib Anamorelin (hydrochlorid Azilsartan Ceftaroline Choline Elvitegravir tetraphosphat Rolapitant Favipiravir Empty e) medoxomil fosamil Fenofibrate e Imeglimin Teneligliptin f Empty (hydrochlorid Mirabegron Nesbuvir Riociguat (R)-Elagolix Palifosfamide Radezolid Tasimelteon (hydrobromid Tosedostat Empty e) e) Givinostat 1- Omadacyclin g Empty Indeglitazar Sobetirome Ataluren (hydrochlorid Tafamidis Tedizolid Deoxynojirimy e Selexipag Tideglusib Empty e meglumine (phosphate) cin (hydrochlorid Avibactam Migalastat h Empty Topiroxostat Anagliptin Avibactam (sodium Eliglustat Eliglustat Ipragliflozin Azilsartan Capadenoson (hydrochlorid Empty (sodium) hydrate) (hemitartrate) e) Plate layout: CS-L052-7 1 2 3 4 5 6 7 8 9 10 11 12 Pardoprunox 5- a Empty Pafuramidine Prinaberel Succinobucol Amifampridin Ozenoxacin (hydrochlorid Sofosbuvir Aminosalicylic ATB-346 Naproxen Empty e e) Acid Icotinib Buparlisib b Empty Naproxen Talampanel (Hydrochlorid (Hydrochlorid Avosentan Tonabersat Ganetespib RX-3117 Letermovir Alpelisib Empty (sodium) e) e) Nelfinavir Eltrombopag
Load more

Recommended publications
  • PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
    International Journal of Molecular Sciences Review PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects Rosalin Mishra , Hima Patel, Samar Alanazi , Mary Kate Kilroy and Joan T. Garrett * Department of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267-0514, USA; [email protected] (R.M.); [email protected] (H.P.); [email protected] (S.A.); [email protected] (M.K.K.) * Correspondence: [email protected]; Tel.: +1-513-558-0741; Fax: +1-513-558-4372 Abstract: The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian, colorectal, prostate, glioblastoma and endometrial cancers. PI3K signaling plays an important role in cancer cell survival, angiogenesis and metastasis, making it a promising therapeutic target. There are several ongoing and completed clinical trials involving PI3K inhibitors (pan, isoform-specific and dual PI3K/mTOR) with the goal to find efficient PI3K inhibitors that could overcome resistance to current therapies. This review focuses on the current landscape of various PI3K inhibitors either as monotherapy or in combination therapies and the treatment outcomes involved in various phases of clinical trials in different cancer types. There is a discussion of the drug-related toxicities, challenges associated with these PI3K inhibitors and the adverse events leading to treatment failure. In addition, novel PI3K drugs that have potential to be translated in the clinic are highlighted. Keywords: cancer; PIK3CA; resistance; PI3K inhibitors Citation: Mishra, R.; Patel, H.; Alanazi, S.; Kilroy, M.K.; Garrett, J.T.
    [Show full text]
  • Présentation HJ
    Conflits d’intérêts Astra-Zeneca, Janssen, Abacus international, Laboratoire ETAP, Institut Pasteur. Dr Hervé JAVELOT Pharmacien PH Etablissement Public de Santé Alsace Nord Service Pharmacie 141 avenue de Strasbourg 67 170 BRUMATH Tél. : 03 88 64 61 70 Fax : 03 88 64 61 58 Mail : [email protected] Perspectives dans la psychopharmacologie de l’anxiété et de la dépression Hervé JAVELOT Etablissement Public de Santé Alsace Nord Perspectives dans la psychopharmacologie de l’anxiété et de la dépression Traitements des troubles anxio-dépressifs. Les perspectives. ◦ L’axe GABAergique…éternellement prometteur ? ◦ L’incontournable théorie « monoaminergique »… ◦ Des théories alternatives à suivre … Traitements des troubles anxio-dépressifs. Contexte : ◦ XXI ème siècle : Le « siècle de la dépression » s’installe ? (Hardeveld et al., 2010) L’« ère de l’angoisse » s’affirme ? (Auden, 1947) ◦ Prévalence au cours de la vie : 16 à 17% pour la dépression, 17 à 18% pour les troubles anxieux Co-morbidité des 2 troubles dans 20 à 40% des cas (Antony, 2011 ; Depping et al., 2010 ; Hardeveld et al., 2010 ; Huppert, 2009) Auden WH (1947). The Age of Anxiety: A Baroque Eclogue. Random House: New York. Hardeveld F, Spijker J, De Graaf R, Nolen WA, Beekman AT. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand. 2010;122(3):184-91. Antony MM. Recent advances in the treatment of anxiety disorders. Canadian Psychology 2011;52(1), 10-19. Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010;(12):CD008120. Huppert JD. Anxiety disorders and depression comorbidity.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Beyond Monoamines Towards the Development of Novel Antidepressants Oltre Le Monoamine Al Fine Di Sviluppare Nuovi Farmaci Antidepressivi
    Original article • Articolo originale Beyond monoamines towards the development of novel antidepressants Oltre le monoamine al fine di sviluppare nuovi farmaci antidepressivi M. Fornaro1,2 1 Department of “Scienze della Formazione”, University of Catania, Italy; 2 Department of Psychiatry, Veteran Affairs (VA) Hospital, University of California (UCSD), La Hoya, San Diego, CA, USA Summary ated giving priority to RCTs and meta-analyses. At present, the pharmacological management of depression appears is Objective characterized by a wide variety of different augmentation or Herein, a concise review is presented on the current and most switching approaches (Fig. 1). Nonetheless, response rates promising antidepressant pharmacological agents for manage- remain substantially unsatisfactory, thus prompting for the ment of depression. development of novel agents with different mechanisms of action. Materials and methods A PubMed search (1966 - February 2012) was performed using Conclusions the following keywords or their combination: “depression”; Shifting the interest for novel antidepressant drugs beyond the “major depressive disorder”: “antidepressants”; “novel antide- monoaminergic modulation represents (Tables I-III) an intriguing pressant targets”; “monoamine”; “novel antidepressants”. Ad- opportunity to enhance response rates of depression, although ditional literature sources, including most authoritative and up- other issues, including revision of current nosological bounda- dated edited books or pamphlets were examined accordingly.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • 42711 IPEG Programmaboekje
    19 th Biennial Conference 19th Biennial Conference October 26th – 30th 2016 October 26 Nijmegen, the Netherlands th – 30 th 2016 Nijmegen, the Netherlands 2016 Nijmegen, 42711 IPEG programmaboekje omslag.indd 1 06-10-16 17:52 The “International Pharmaco-EEG Society, Association for Electrophysiological Brain Research in Preclinical and Clinical Pharmacology and Related Fields” (IPEG) is a non-profit organization, established in 1980 and composed of scientists and researchers actively involved in electrophysiological brain research in preclinical and clinical pharmacology, neurotoxicology and related areas of interest. my.thesis nl for the design of your Thesis & to show your Thesis 42711 IPEG programmaboekje omslag.indd 2 06-10-16 17:52 IPEG 2016 in Nijmegen | 1 Welcome to Nijmegen, dear attendants of the 19th IPEG meeting. Nijmegen, a 2000 year old city; Nijmegen, a Roman and a medieval city; Nijmegen, the home town of the first catholic university funded by the Faithfull to improve education of a suppressed part of the Netherlands; Nijmegen, the city that heavily suffered in WWII; Nijmegen, the home town of the Donders Institute. Nijmegen, as we hope and trust, your home town for the upcoming IPEG meeting. As you all know, electrophysiological brain research has a long tradition going back as far as 1875 when the first report on the animal electroencephalogram (EEG) was published by Caton. The often forgotten Polish physiologist Adolf Beck was also a EEG pioneer many years before Hans Berger’s initial reports. Beck recorded electrical potentials in several brain areas evoked by peripheral sensory stimuli. Using this technique, Beck localised various centres in the brain of several animal species and described desynchronization in electrical brain potentials.
    [Show full text]
  • 19Th Biennial IPEG Meeting Nijmegen, the Netherlands
    Neuropsychiatric Electrophysiology 2016, 2(Suppl 1):8 DOI 10.1186/s40810-016-0021-4 MEETINGABSTRACTS Open Access 19th biennial IPEG Meeting Nijmegen, The Netherlands. 26-30 October 2016 Published: 29 November 2016 Training course measures. This will be illustrated by means of pertinent examples. These include elucidating the mechanisms of stimulant action re- A1 mediating deficient impulse control and the role of the cannabinoid Thalamocortical sleep oscillations system in human working memory, as well as drug effects on Igor Timofeev1,2 sensory gating and specific aspects of visual-spatial attention. Other 1Department of Psychiatry and Neuroscience, Université Laval, Québec, examples concern the added sensitivity of EEG and ERP measures, Canada; 2Centre de recherche de l’Institut universitaire en santé mentale relative to that of performance measures, in detecting effects of alco- de Québec (CRIUSMQ), Université Laval, Québec, Canada hol, and more generally in monitoring and predicting vigilance and Neuropsychiatric Electrophysiology 2016, 2(Suppl 1):A1 the ability to detect external signals in the immediate future. Rela- tions between brain signals and cognitive competences are revealed In waking and sleeping states, thalamocortical system generates a by either comparing different individuals, or moment-to-moment variety of oscillations ranging from 0.1 Hz to hundreds of Hz. Most of fluctuations within individuals, or differences in state (e.g., drug- them are present during NREM sleep, but slower activities prevail in induced) within individuals. this state of vigilance. Thalamocortical network is organized in a loop in which thalamocortical cells excite reticular thalamic and neocor- tical cells, reticular thalamic cells inhibit thalamocortical cells and A3 corticothalamic cells excite thalamocortical and reticular thalamic EEG and ERP as key techniques for functional brain alterations cells.
    [Show full text]
  • Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance
    biomedicines Review Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance Marta Araujo-Castro 1,* , Eider Pascual-Corrales 1 , Javier Molina-Cerrillo 2 and Teresa Alonso-Gordoa 2 1 Neuroendocrinology Unit, Endocrinology and Nutrition Department, Ramón y Cajal Health Research Institute (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain; [email protected] 2 Medical Oncology Department, Ramón y Cajal Health Research Institute (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain; [email protected] (J.M.-C.); [email protected] (T.A.-G.) * Correspondence: [email protected] Abstract: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with limited treatment options in the advanced stages. Immunotherapy offers hope for altering the orthodox management of cancer, and its role in advanced ACC has been investigated in different studies. With the aim clarifying the role of immunotherapy in ACC we performed a comprehensive review about this topic focusing on the predictors of response, efficacy, safety, and the mechanisms of resistance. Five clinical trials with four immune checkpoint inhibitors (pembrolizumab, avelumab, nivolumab, and ipilimumab) have investigated the role of immunotherapy in advanced ACC. Despite, the different primary endpoints used in these studies, the reported rates of overall response rate and progression free survival were generally poor. Three main potential markers of response to immunotherapy Citation: Araujo-Castro, M.; in ACC have been described: Expression of PD-1 and PD-L1, microsatellite instability and tumor Pascual-Corrales, E.; Molina-Cerrillo, mutational burden. However, none of them has been validated in prospective studies. Several J.; Alonso-Gordoa, T.
    [Show full text]
  • Horizon Scanning Status Report June 2019
    Statement of Funding and Purpose This report incorporates data collected during implementation of the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System, operated by ECRI Institute under contract to PCORI, Washington, DC (Contract No. MSA-HORIZSCAN-ECRI-ENG- 2018.7.12). The findings and conclusions in this document are those of the authors, who are responsible for its content. No statement in this report should be construed as an official position of PCORI. An intervention that potentially meets inclusion criteria might not appear in this report simply because the horizon scanning system has not yet detected it or it does not yet meet inclusion criteria outlined in the PCORI Health Care Horizon Scanning System: Horizon Scanning Protocol and Operations Manual. Inclusion or absence of interventions in the horizon scanning reports will change over time as new information is collected; therefore, inclusion or absence should not be construed as either an endorsement or rejection of specific interventions. A representative from PCORI served as a contracting officer’s technical representative and provided input during the implementation of the horizon scanning system. PCORI does not directly participate in horizon scanning or assessing leads or topics and did not provide opinions regarding potential impact of interventions. Financial Disclosure Statement None of the individuals compiling this information have any affiliations or financial involvement that conflicts with the material presented in this report. Public Domain Notice This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated. All statements, findings, and conclusions in this publication are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI) or its Board of Governors.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 24, No. 4, 2010 World Health Organization WHO Drug Information Contents WHO Prequalification Sitaxentan: worldwide withdrawal 307 Programmes Sibutramine: suspension of sales 307 Sibutramine-containing medicines: WHO Prequalification of Medicines withdrawal 308 Programme: survey of service Testosterone transdermal patch: quality provided to manufacturers 293 withdrawal of extension of WHO initiates pilot prequalification of indication application 308 active pharmaceutical ingredients 297 Aliskiren/valsartan: withdrawal of New on-line database for WHO marketing authorization application 308 prequalified vaccines 298 Mometasone furoate/formoterol fumarate: withdrawal of marketing Safety and Efficacy Issues authorization application 309 EMA and US FDA extend confidentiality H1N1 influenza vaccine: narcolepsy 299 arrangements indefinitely 309 Statins: interstitial lung disease 299 Tocilizumab: risk of fatal anaphylaxis 300 Recent Publications, Pioglitazone: potential bladder cancer 301 Information and Events Angiotensin receptor blockers and US Government to share patents with cancer: safety review 301 Medicines Patent Pool 310 GnRH agonists, diabetes and cardio- Clinical trials and global medicines vascular disease 301 development 310 Gadolinium-based contrast agents: Evaluation of future nanomedicines 311 kidney dysfunction 302 Reporting on opioid inaccessibility 311 Lamotrigine: aseptic meningitis Tinzaparin sodium: renal Impairment in elderly 303 Consultation Documents Tamoxifen: drug interactions involving The
    [Show full text]